uniQure N.V. (NASDAQ:QURE) Stock Has Average Price Target of $56.83 According to Analysts

Key Points

• Analyst sentiment is moderately positive: Of 16 analysts covering uniQure, 11 rate it Buy, one Strong Buy, three Hold, and one Sell; the average 12-month price target is $56.83.
• Recent analyst views varied: Wolfe Research upgraded the stock to Outperform with a $65 target, while Goldman Sachs cut its target to $31 and assigned a Neutral rating.
• In its latest reported quarter, uniQure lost $0.88 per share, beating the $0.92 loss analysts expected, but revenue of $5.2 million fell short of the $6.17 million consensus estimate.

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) have been given an average rating of "Moderate Buy" by the sixteen analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $56.83.

QURE has been the subject of a number of research reports. HC Wainwright reiterated a "buy" rating on shares of uniQure in a research report on Tuesday, September 29th. UBS Group started coverage on shares of uniQure in a research report on Thursday, October 15th. They issued a "buy" rating and a $48.00 price target on the stock. Wolfe Research raised shares of uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 price target on the stock in a research note on Wednesday, July 29th. The Goldman Sachs Group lowered their price objective on shares of uniQure from $46.00 to $31.00 and set a "neutral" rating for the company in a research report on Wednesday, September 30th. Finally, Weiss Ratings raised shares of uniQure from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, September 21st.

Hedge Funds Weigh In On uniQure

A number of large investors have recently made changes to their positions in QURE. Seven Fleet Capital Management LP bought a new position in uniQure in the second quarter worth approximately $15,254. IFP Advisors Inc grew its holdings in uniQure by 39.8% in the second quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company's stock worth $128,000 after purchasing an additional 791 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in uniQure during the 3rd quarter worth $86,000. Fulton Bank N.A. purchased a new position in uniQure during the 2nd quarter worth $220,000. Finally, Activest Wealth Management acquired a new position in uniQure during the 3rd quarter valued at about $121,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Price Performance

Shares of QURE stock traded down $0.82 on Friday, hitting $23.81. 1,394,467 shares of the stock traded hands, compared to its average volume of 1,965,420. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.52 and a quick ratio of 11.52. uniQure has a 52 week low of $8.73 and a 52 week high of $51.72. The firm has a 50 day simple moving average of $29.50 and a two-hundred day simple moving average of $29.68. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -6.78 and a beta of 1.14.

uniQure (NASDAQ:QURE - Get Free Report) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. The company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $6.17 million. uniQure had a negative return on equity of 96.34% and a negative net margin of 1,154.84%. As a group, equities research analysts predict that uniQure will post -3.83 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients' cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington's disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.